Insulin Shortage 2026: Status, Causes & Alternatives

Ask ten people with diabetes whether there's an insulin shortage in 2026, and you'll get ten different answers depending on which product they use and where they fill it. That's because "insulin" isn't one drug — it's a family of long-acting, rapid-acting, and premixed products made by three manufacturers, and 2026's supply problems are hitting different corners of that family for different reasons. This guide separates fact from headline: what's actually short, what's fine, why it happened, and what to do if you're the one standing at the counter with an empty prescription bottle.

1. Is There Really an Insulin Shortage in 2026?

Partially, and unevenly. The FDA's Drug Shortages Database and the ASHP/University of Utah Drug Shortage Resource Center — the two authoritative trackers pharmacists actually use — currently list several individual insulin products as being in shortage, including insulin aspart, insulin degludec, and insulin glargine-yfgn (the Semglee biosimilar). That's a real, documented supply problem. But it isn't a blanket shortage of "insulin" as a category — vials of Lantus, most forms of Humalog, Basaglar, Rezvoglar, and Toujeo are generally available at the national level, even while specific formats like Lantus SoloStar pens sit on intermittent back order.

2. Why This Is Happening: Four Overlapping Causes

Unlike a single-drug shortage caused by one factory issue, the 2026 insulin supply picture is the result of several separate decisions landing in the same window.

Cause 1: The Semglee discontinuation

Cause 2: Novo Nordisk's lineup streamline

Separately, Novo Nordisk discontinued its unbranded (authorized generic) insulin aspart and insulin degludec products, along with older NovoLog vial, FlexPen, and PenFill formats, effective December 31, 2025. The company paired this with list price cuts of up to 75% on remaining products starting January 1, 2026. The intent was to simplify the product line and lower list prices, but the near-term effect was fewer SKUs on the shelf while patients and pharmacies adjusted.

Cause 3: The Basaglar Tempo pen phase-out

Eli Lilly is separately discontinuing its Basaglar Tempo smart-pen platform. New Tempo pens are available only through July 27, 2026; the Tempo app stopped recording new dose data the following day, and the broader TempoSmart platform is scheduled to shut down entirely by the end of 2026. This doesn't affect standard Basaglar KwikPen supply, but it's a real transition Tempo users need to plan around.

Cause 4: GLP-1 demand pulling on the same manufacturing capacity

Novo Nordisk and Eli Lilly are the same companies making Ozempic, Wegovy, Mounjaro, and Zepbound — and demand for those drugs has grown faster than either company anticipated. Both companies have publicly stated that insulin production hasn't been deprioritized, but diabetes advocates have repeatedly raised concerns that manufacturing capacity, glass vials, and injection-device components are being pulled toward the more profitable GLP-1 category, indirectly straining insulin supply chains during periods of high demand.

3. Timeline: How We Got Here

4. Current Availability by Insulin Type

Availability shifts week to week and varies by region and pharmacy chain. This table reflects national manufacturer and ASHP shortage-list status as of early August 2026 — always confirm with your specific pharmacy before assuming a product is in or out of stock.

5. Alternatives: What's Actually in Stock

If your usual insulin isn't available, here's how the substitutes line up by category. None of these are automatic pharmacy substitutions the way an interchangeable biosimilar is — most need a new prescription or at least a phone call to your prescriber's office.

For deeper cost comparisons across brands, see our insulin price comparison by brand and pharmacy, and if cost — not just availability — is the real obstacle, our complete guide to free and $35 insulin walks through every current program in one place.

6. Pros & Cons of Switching Insulin Products

7. Step-by-Step: What to Do If Your Pharmacy Is Out

8. Eligibility Comparison: Programs That Can Help

Supply gaps often collide with cost concerns — if you're being pushed onto a new product anyway, it's worth knowing what assistance is available for it. Here's how the major insulin cost programs compare on who qualifies.

9. Income Limit Comparison

Income thresholds are published as a percentage of the Federal Poverty Level (FPL) and adjusted each year, so treat the dollar figures below as current 2026 approximations — always confirm the exact number for your household size at Medicare.gov or the program's own site before applying.

10. Covered Medications by Program

11. Application Process

12. Approval Timelines

13. Renewal Process

Patient assistance programs are not one-and-done. Most require annual re-enrollment, and none of them renew automatically:

• NovoCare PAP: Re-apply annually with updated income documentation; renewal reminders are typically sent 60–90 days before expiration.
• Lilly Cares Foundation: Enrollment generally covers a set period (commonly up to a year), after which you must reapply and requalify under the current FPL guidelines.
• Medicare Extra Help: The Social Security Administration reviews eligibility each year, usually using tax return data; a change in income or resources can trigger a reassessment mid-year.
• Savings cards (Lilly Insulin Value Program): These generally don't expire the same way — check your card's terms, since some require annual re-registration to keep the same card number active.

14. Common Mistakes to Avoid

• Waiting until the pharmacy says "no" to start looking for alternatives. By then you may have days, not weeks, of supply left.
• Assuming a PAP application that worked last year still applies. Income limits, covered medications, and manufacturer rules change — Novo Nordisk's Ozempic threshold dropped from 400% to 200% FPL as part of 2026 program changes, for example.
• Switching insulin concentration without adjusting the dose. Moving to Toujeo (300 units/mL) using your old Lantus (100 units/mL) unit count is a dosing error, not a substitution.
• Skipping the Medicaid denial letter step. Some uninsured-patient programs require proof of a Medicaid denial before they'll process your application — submitting without it just delays things.
• Not checking whether your product has an interchangeable biosimilar. Interchangeable products like Kirsty can be substituted at the pharmacy immediately, without waiting on your prescriber.

15. Decision Tree: What Should You Do Right Now?

16. Cost: What You Should Actually Pay

Regardless of the supply situation, no one should be paying list price for insulin in 2026 if they can help it. Medicare enrollees pay no more than $35 per month per covered insulin under the Inflation Reduction Act, with no deductible applied. Eli Lilly's savings card caps insulin at $35 a month for insured and uninsured patients alike, with no income verification required at the pharmacy counter. If you qualify for a Humalog savings card or want to compare pricing across pharmacies, see our insulin price comparison guide. For a full rundown of every free and low-cost insulin option, including how Novo Nordisk's patient assistance program and the Eli Lilly Patient Assistance Program work end to end, read our complete guide to free or $35 insulin in 2026.

If you're on Medicare and cost is the bigger issue than availability, it's worth checking whether recent Part D changes affect your specific plan, and whether you qualify for Extra Help — many eligible people never apply simply because they assume their income is too high.